Xilio (XLO) - Volume dana dhuwit perusahaan

Simbol resmi perusahaan Xilio Therapeutics Inc (XLO)

Xilio Therapeutics, Inc. (XLO) operates in the high-risk targeted immunology sector, characterized by intense patent battles with industry behemoths. A narrow development profile creates a dependency on the outcomes of current trials; however, competent management and a partnership with Gilead ensure process transparency. Cash reserve dynamics confirm the availability of funds, with the current metric standing at 0.11.

XLO - Cadangan dhuwit perusahaan xiliotx.com ing rentang 04.07.2022 - 21.11.2026

Rincian analitis perusahaan Xilio Therapeutics, Inc.

Pambiji fundamental perusahaan:Xilio Therapeutics
Produk merek Xilio Therapeutics, Inc.

For Xilio Therapeutics, Inc. (XLO), which develops targeted molecules to combat severe forms of cancer, liquidity volume is critical for funding costly research. This cash-on-hand metric measures the total mass of available capital relative to the asset's market value, allowing investors to assess the risk of a cash crunch or the efficiency of utilizing reserves to implement the long-term business development strategy.

Pesaing Xilio Therapeutics, Inc. (XLO)

Volume dana dhuwit perusahaan ONC|HALO - Cadangan dhuwit perusahaan|Revolution Medicines - Dhuwit awis perusahaan|Volume dana dhuwit perusahaan Ascentage Pharma AAPG|CGON - Dana dhuwit perusahaan|Total volume dana dhuwit perusahaan URGN|BCAX: Volume dana dhuwit perusahaan|PSNL - Aset likuid perusahaan|ERAS (Erasca Inc) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan Delcath Systems Inc DCTH|Dana dhuwit perusahaan YmAbs (YMAB)|Aset likuid perusahaan Aura Bio|Volume dana dhuwit perusahaan CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Cadangan dhuwit perusahaan|SELLAS Life Sciences Group - Volume dana dhuwit perusahaan|ACTU - Volume dana dhuwit perusahaan|CTOR: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Volume dana dhuwit perusahaan|Fate Therapeutics, Inc. (FATE) - Aset likuid perusahaan|Dhuwit awis perusahaan WHWK (Aadi Bioscience, Inc.)|Aset likuid perusahaan TScan Therapeutics, Inc.|Volume dana dhuwit perusahaan CSBR (Champions Oncology Corp)|Gunggung dana dhuwit perusahaan XBIT (XBiotech USA)|CVM - Dana dhuwit perusahaan|Sisa dhuwit perusahaan OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Dana dhuwit perusahaan|ARTV: Gunggung dana dhuwit perusahaan|ANL (adlainortye.com) - Volume dana dhuwit perusahaan|VERU: Sisa dhuwit perusahaan|Dhuwit awis perusahaan TPST (Tempest Tx)|Dhuwit awis perusahaan Renovaro RENB|Volume dana dhuwit perusahaan MURA (Mural Oncology PLC)|KAPA - Dhuwit awis perusahaan|OnKure Therapeutics - Volume dana dhuwit perusahaan|w2.cytomed.sg - Gunggung dana dhuwit perusahaan|Curis Corp (CRIS) - Dana dhuwit perusahaan|Cadangan dhuwit perusahaan Apollomics Corp (APLM)|Dana dhuwit perusahaan Tharimmune|Volume dana dhuwit perusahaan advanbiomed.com|Dana dhuwit perusahaan Genprex, Inc (GNPX)|Aset likuid perusahaan Calidi Biotherapeutics, Inc.|Volume dana dhuwit perusahaan SBFM (Sunshine Biopharma Inc.)|XBIO - Dhuwit awis perusahaan|SLRX: Dhuwit awis perusahaan|Sisa dhuwit perusahaan PPBT (Purple Biotech Ltd.)|AONC: Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan BeOne Medicines (BGNE)|Dana dhuwit perusahaan Checkpoint Therapeutics, Inc.|Dhuwit awis perusahaan Elevation Oncology (ELEV)|Dana dhuwit perusahaan iCAD Corp (ICAD)|Dhuwit awis perusahaan Ikena IKNA|Volume dana dhuwit perusahaan NTBL (notablelabs.com)|VIRX - Dhuwit awis perusahaan|MOR: Dhuwit awis perusahaan|NAYA - Volume dana dhuwit perusahaan|Ascentage Pharma (AAPGV) - Dana dhuwit perusahaan